Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib tosylate and pravastatin may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of
liver cancer by blocking blood flow to the tumor. It is not yet known whether sorafenib
tosylate is more effective when given alone or together with pravastatin in treating patients
with liver cancer and cirrhosis.
PURPOSE: This randomized phase III trial is studying sorafenib tosylate given together with
pravastatin to see how well it works compared with giving sorafenib tosylate alone in
treating patients with liver cancer and cirrhosis.